Korro to Join June Investor and Scientific Conferences

Korro Bio, Inc. (Nasdaq: KRRO), a biopharmaceutical company based in Cambridge, Massachusetts, has announced its participation in several forthcoming investor and scientific conferences. The company's management team will present and discuss their latest advancements and strategic initiatives.

At the Jefferies Global Healthcare Conference, Korro’s Chief Executive Officer and President, Ram Aiyar, Ph.D., is scheduled to present on June 6, 2024, at 2:00 p.m. ET. He will be joined by Chief Financial Officer, Vineet Agarwal, who will also participate in the event. This conference is a significant opportunity for Korro to share its progress and future plans with investors and stakeholders.

Korro Bio will also be represented at the 2024 Alpha-1 Foundation National Conference. Chief Medical Officer, Kemi Olugemo, M.D., FAAN, will give a presentation on June 8, 2024, at 11:20 a.m. ET. Dr. Olugemo will discuss Korro's leading RNA editing oligonucleotide candidate, KRRO-110, highlighting its potential as a treatment for Alpha-1 Antitrypsin Deficiency, a rare genetic condition.

Furthermore, the company will take part in the 5th Annual RNA Editing Summit. Venkat Krishnamurthy, Ph.D., Senior Vice President & Head of Platform, RNA Editing, will engage in a roundtable discussion about strategies to enhance the longevity of RNA editing therapeutics for more durable effects. This discussion is set for June 20, 2024, at 11:00 a.m. ET. Later that day, at 1:30 p.m. ET, Dr. Krishnamurthy will present "Edit the Message: Rewrite the Future," which will provide updates on Korro's proprietary OPERA platform (Oligonucleotide Promoted Editing of RNA) and its advancement towards clinical applications.

A live webcast of the Jefferies presentation will be available on the “Events & Presentations” page in the Investor section of Korro’s website. Additionally, a replay of the event will be accessible for 30 days following the presentation.

Korro Bio is dedicated to developing innovative genetic medicines for both rare and common diseases through its unique RNA editing platform. Unlike traditional gene editing technologies that target DNA, Korro focuses on editing RNA to achieve precise, transient single-base edits. This method not only enhances the specificity and tunability of genetic medicines but also improves their long-term tolerability. The company leverages its proprietary platform, established delivery methods, manufacturing expertise, and regulatory knowledge to bring these groundbreaking therapies to patients.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!